Company news
Pavmed Inc. (NASDAQ:PAVM) news
Pavmed Inc. news releases on 6ix. Latest, Oct 31, 2024: PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
Press releases — page 2
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
October 30, 2024
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
October 9, 2024
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
September 15, 2024
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
August 12, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
July 29, 2024
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
June 12, 2024
PAVmed Provides Business Update and First Quarter 2024 Financial Results
May 12, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
May 2, 2024
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
April 29, 2024
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
March 25, 2024
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
March 20, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
March 12, 2024
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
February 7, 2024
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
December 10, 2023
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
December 3, 2023
PAVmed Provides Business Update and Third Quarter Financial Results
November 13, 2023
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
October 31, 2023
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
October 30, 2023
PAVmed Provides Business Update and Second Quarter Financial Results
August 14, 2023
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023
July 30, 2023
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
June 27, 2023
PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
June 1, 2023
PAVmed Provides Business Update and First Quarter Financial Results
May 15, 2023
PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
May 4, 2023
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
April 24, 2023
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023
March 2, 2023
PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform™ Goes Live
February 27, 2023
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
December 14, 2022
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
November 14, 2022
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022
November 2, 2022
PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results
August 15, 2022
PAVmed to Hold a Business Update Conference Call on August 16, 2022
August 2, 2022
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
May 11, 2022
PAVmed to Hold a Business Update Conference Call on May 12, 2022
April 25, 2022
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
March 23, 2022
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
March 22, 2022
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
March 16, 2022
PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board
March 9, 2022
PAVmed to Hold a Business Update Conference Call on March 29, 2022
March 7, 2022
PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
March 2, 2022
PAVmed Appoints Shaun O’Neil as Chief Operating Officer
February 23, 2022
PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
November 30, 2021
PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results
November 15, 2021
PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer
October 24, 2021
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
October 6, 2021
PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results
August 11, 2021
PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
August 9, 2021
Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
August 2, 2021